GLP 1 Agonists

This hub provides a comprehensive overview of GLP-1 receptor agonists, semaglutide, and related peptide therapeutics, integrating the latest scientific evidence and clinical perspectives. The linked articles examine the mechanisms of GLP-1–based therapies in weight loss, diabetes management, and beyond, as well as their emerging roles in addressing conditions such as alcohol addiction and menopause-related metabolic changes. Readers will find detailed discussions on efficacy, safety, patient selection, and the comparative potential of novel molecules like berberine. The collection also explores broader trends in peptide therapeutics and the future landscape of targeted treatment. This resource is designed for healthcare professionals, researchers, and individuals seeking authoritative, evidence-based information on GLP-1 and peptide-based interventions.

How Oral GLP-1 Drugs Work For Weight Loss

Discover how next-generation oral GLP-1 therapies are transforming weight management by breaking through the stomach’s toughest barriers and opening the door to powerful, needle-free metabolic treatments.

Overview

Explore authoritative articles on GLP-1, semaglutide, peptide therapeutics, weight loss, diabetes, and emerging treatments. This hub delivers evidence-based insights for clinicians, researchers, and anyone interested in targeted therapies.

Recent Advancements in Treatment for Parkinson’s Disease

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Wegovy: A Breakthrough in Weight Loss?

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

Multiple Endocrine Neoplasia Type 1 (MEN1)

How Does Semaglutide Work to Lose Weight?

The Potential of Peptide Therapeutics in Treating Chronic Diseases

The Future of Diabetes Treatment

The Unexpected Effects of GLP-1 Medications on Women’s Health

Are GLP-1 Drugs the Future of Alcohol Addiction Treatment?

Is Berberine Really “Nature’s Ozempic”? What Science Says

See more featured articles »

Who Should Take Weight Loss Injections, and Who Shouldn’t?

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Top Nutrients and Habits That Boost GLP-1 Naturally

What Are Advanced Glycation End Products and Why They Matter

The Impact of Glucagon on Diabetes Management

The Natural Molecule That Could Rival Ozempic

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide and Weight Loss in Menopause

Gut-Brain Axis and Obesity

Peptide Therapy: The Future of Targeted Treatment?

Latest GLP 1 Agonists News and Research

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.

22 Mar 2026

GLP-1 medications linked to reduced psychiatric hospital visits

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows.

18 Mar 2026

Stopping GLP-1 treatment linked to increase in risk of major cardiovascular events

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular benefits.

18 Mar 2026

Study finds GLP-1 medicines cut fat while preserving muscle function

Researchers found that GLP-1 medicines caused weight loss mainly through fat reduction, with only modest decreases in absolute muscle mass and no disproportionate loss of muscle function. In mice, physical performance improved, while in a small 12-week human pilot trial, strength was preserved despite reduced thigh muscle size.

18 Mar 2026

Weight-loss drugs linked to preterm birth risk in women with pre-existing diabetes

Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early pregnancy to treat pre-existing diabetes.

17 Mar 2026

Patients who stop GLP-1 drugs often restart or try alternatives

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

17 Mar 2026

Why do some people respond better to GLP-1 drugs? Gut microbiome may hold clues

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment outcomes. The authors conclude that microbiome changes seen during therapy are most likely driven by diet, behavior, and weight loss, although microbial profiling may eventually help predict patient responses.

15 Mar 2026

Real-world study shows modest weight regain after GLP-1 discontinuation

As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings.

12 Mar 2026

Wegovy linked to higher risk of eye stroke and vision loss

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of 'eye stroke' (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.

10 Mar 2026

Most weight lost on GLP-1 drugs returns within a year after stopping

The cessation of GLP-1RAs is linked to a 60% weight regain within a year, emphasizing the importance of tailored strategies for effective long-term weight loss.

9 Mar 2026

Engineered lettuce may turn injectable GLP-1 therapies into oral pills

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved by the FDA for the treatment of type 2 diabetes, they have since also transformed the therapeutic landscape of obesity and weight management.

6 Mar 2026

Drug combination shows greater weight loss while preserving muscle mass

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue.

5 Mar 2026

GLP-1 drugs may be effective at treating and preventing substance use disorders

Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be effective at treating and preventing substance use disorders across all major addictive substances studied, suggesting these drugs target a common biological pathway underlying addiction.

4 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

The surprising neurological benefits of GLP-1s

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study released March 1, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

2 Mar 2026

Barshop Institute at UT Health San Antonio secures major federal funding for longevity trial

Positioning The University of Texas at San Antonio as a national anchor for aging and longevity science, its Sam and Ann Barshop Institute for Longevity and Aging Studies will receive up to $38 million in federal funding for the first nationwide clinical study in healthy longevity.

24 Feb 2026

ARPA-H-funded PROSPR program focuses on the biological hallmarks of aging

Columbia University Mailman School of Public Health has received an award as part of the PROactive Solutions for Prolonging Resilience (PROSPR) program within the Advanced Research Projects Agency for Health (ARPA-H) to accelerate research on the biological hallmarks of aging.

24 Feb 2026

Untreated sleep apnea may cost the UK and US billions annually

Untreated obstructive sleep apnea may be costing the UK and US economies billions of pounds/dollars in lost productivity every year, with a considerable proportion of working age adults experiencing symptoms indicative of the breathing disorder, suggests an analysis published online in the journal Thorax.

24 Feb 2026

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026